These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 19944558)

  • 1. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
    Durez P; Nzeusseu Toukap A; Lauwerys BR; Manicourt DH; Verschueren P; Westhovens R; Devogelaer JP; Houssiau FA
    Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
    Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
    J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M; Nurmohamed MT; Wolbink G; Voskuyl AE; de Koning M; van de Stadt R; Twisk JW; Dijkmans BA; Lems WF
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.
    Saiki O; Takao R; Naruse Y; Kuhara M; Imai S; Uda H
    J Rheumatol; 2007 Oct; 34(10):1997-2004. PubMed ID: 17787045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis.
    Arvidson NG; Larsen A; Aaseth J; Larsson A
    Scand J Clin Lab Invest; 2007; 67(3):337-42. PubMed ID: 17454848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis.
    van Eijk IC; Tushuizen ME; Sturk A; Dijkmans BA; Boers M; Voskuyl AE; Diamant M; Wolbink GJ; Nieuwland R; Nurmohamed MT
    Ann Rheum Dis; 2010 Jul; 69(7):1378-82. PubMed ID: 19919943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
    Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.
    Paulus HE; Ramos B; Wong WK; Ahmed A; Bulpitt K; Park G; Sterz M; Clements P
    J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.